Influenza Virus H5 DNA Vaccination is Immunogenic by Intramuscular and Intradermal Routes in Humans

Overview

Journal Clin Vaccine Immunol

Publisher American Society for Microbiology

Specialties Allergy & Immunology
Pathology

Date 2012 Sep 8

PMID 22956656

Citations 28

Authors

J E Ledgerwood

Z Hu

I J Gordon

G Yamshchikov

M E Enama

S Plummer

R Bailer

M B Pearce

T M Tumpey

R A Koup

J R Mascola

G J Nabel

B S Graham

Affiliations

Soon will be listed here.

Abstract

Avian influenza virus causes outbreaks in domestic and wild birds around the world, and sporadic human infections have been reported. A DNA vaccine encoding hemagglutinin (HA) protein from the A/Indonesia/5/05 (H5N1) strain was initially tested in two randomized phase I clinical studies. Vaccine Research Center study 304 (VRC 304) was a double-blinded study with 45 subjects randomized to placebo, 1 mg of vaccine, or 4 mg of vaccine treatment groups (n = 15/group) by intramuscular (i.m.) Biojector injection. VRC 305 was an open-label study to evaluate route, with 44 subjects randomized to intradermal (i.d.) injections of 0.5 mg by needle/syringe or by Biojector or 1 mg delivered as two 0.5-mg Biojector injections in the same deltoid or as 0.5 mg in each deltoid (n = 11/group). Injections were administered at weeks 0, 4, and 8 in both studies. Antibody responses to H5 were assessed by hemagglutination inhibition (HAI) assay, enzyme-linked immunosorbent assay (ELISA), and neutralization assay, and the H5 T cell responses were assessed by enzyme-linked immunospot and intracellular cytokine staining assays. There were no vaccine-related serious adverse events, and the vaccine was well tolerated in all groups. At 1 mg, i.d. vaccination compared to i.m. vaccination induced a greater frequency and magnitude of response by ELISA, but there were no significant differences in the frequency or magnitude of response between the i.d. and i.m. routes in the HAI or neutralization assays. T cell responses were more common in subjects who received the 1- or 4-mg dose i.m. These studies demonstrated that the DNA vaccine encoding H5 is safe and immunogenic and served to define the proper dose and route for further studies. The i.d. injection route did not offer a significant advantage over the i.m. route, and no difference was detected by delivery to one site versus splitting the dose between two sites for i.d. vaccine administration. The 4-mg dose (i.m) was further investigated in prime-boost regimens.

Citing Articles

Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases.

Xu Z, Patel A, Tursi N, Zhu X, Muthumani K, Kulp D Front Med Technol. 2022; 2:571030.

PMID: 35047878 PMC: 8757735. DOI: 10.3389/fmedt.2020.571030.

DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses.

Li H, Wang S, Hu G, Zhang L, Liu S, Lu S Emerg Microbes Infect. 2021; 10(1):833-841.

PMID: 33853515 PMC: 8812797. DOI: 10.1080/22221751.2021.1918026.

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.

Carter C, Houser K, Yamshchikov G, Bellamy A, May J, Enama M PLoS One. 2019; 14(9):e0222178.

PMID: 31532789 PMC: 6750650. DOI: 10.1371/journal.pone.0222178.

MetaCyto: A Tool for Automated Meta-analysis of Mass and Flow Cytometry Data.

Hu Z, Jujjavarapu C, Hughey J, Andorf S, Lee H, Gherardini P Cell Rep. 2018; 24(5):1377-1388.

PMID: 30067990 PMC: 6583920. DOI: 10.1016/j.celrep.2018.07.003.

A Review of DNA Vaccines Against Influenza.

Lee L, Izzard L, Hurt A Front Immunol. 2018; 9:1568.

PMID: 30038621 PMC: 6046547. DOI: 10.3389/fimmu.2018.01568.

References

Bresson J, Perronne C, Launay O, Gerdil C, Saville M, Wood J . Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006; 367(9523):1657-64. DOI: 10.1016/S0140-6736(06)68656-X. View

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

Ledgerwood J, Wei C, Hu Z, Gordon I, Enama M, Hendel C . DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis. 2011; 11(12):916-24. PMC: 7185472. DOI: 10.1016/S1473-3099(11)70240-7. View

Brady R, Treanor J, Atmar R, Keitel W, Edelman R, Chen W . Safety and immunogenicity of a subvirion inactivated influenza A/H5N1 vaccine with or without aluminum hydroxide among healthy elderly adults. Vaccine. 2009; 27(37):5091-5. PMC: 2730950. DOI: 10.1016/j.vaccine.2009.06.057. View

Laddy D, Yan J, Khan A, Andersen H, Cohn A, Greenhouse J . Electroporation of synthetic DNA antigens offers protection in nonhuman primates challenged with highly pathogenic avian influenza virus. J Virol. 2009; 83(9):4624-30. PMC: 2668454. DOI: 10.1128/JVI.02335-08. View

Goji N, Nolan C, Hill H, Wolff M, Noah D, Williams T . Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis. 2008; 198(5):635-41. DOI: 10.1086/590916. View

Beran J, Abdel-Messih I, Raupachova J, Hobzova L, Fragapane E . A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses. Clin Ther. 2011; 32(13):2186-97. DOI: 10.1016/S0149-2918(11)00024-5. View

Ledgerwood J, Pierson T, Hubka S, Desai N, Rucker S, Gordon I . A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011; 203(10):1396-404. PMC: 3080891. DOI: 10.1093/infdis/jir054. View

Wei C, Boyington J, McTamney P, Kong W, Pearce M, Xu L . Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science. 2010; 329(5995):1060-4. DOI: 10.1126/science.1192517. View

10.

POTTER C, Oxford J . Determinants of immunity to influenza infection in man. Br Med Bull. 1979; 35(1):69-75. DOI: 10.1093/oxfordjournals.bmb.a071545. View

11.

Zangwill K, Treanor J, Campbell J, Noah D, Ryea J . Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis. 2008; 197(4):580-3. DOI: 10.1086/526537. View

12.

Wei C, Boyington J, Dai K, Houser K, Pearce M, Kong W . Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med. 2010; 2(24):24ra21. PMC: 3182573. DOI: 10.1126/scitranslmed.3000799. View

13.

Martin J, Sullivan N, Enama M, Gordon I, Roederer M, Koup R . A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol. 2006; 13(11):1267-77. PMC: 1656552. DOI: 10.1128/CVI.00162-06. View

14.

Belshe R . The origins of pandemic influenza--lessons from the 1918 virus. N Engl J Med. 2005; 353(21):2209-11. DOI: 10.1056/NEJMp058281. View

15.

Martin J, Louder M, Holman L, Gordon I, Enama M, Larkin B . A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008; 26(50):6338-43. PMC: 2612543. DOI: 10.1016/j.vaccine.2008.09.026. View

16.

Patel A, Tran K, Gray M, Li Y, Ao Z, Yao X . Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses. Vaccine. 2009; 27(23):3083-9. DOI: 10.1016/j.vaccine.2009.03.023. View

17.

Catanzaro A, Roederer M, Koup R, Bailer R, Enama M, Nason M . Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine. 2007; 25(20):4085-92. DOI: 10.1016/j.vaccine.2007.02.050. View

18.

Stephenson I, Wood J, Nicholson K, Charlett A, Zambon M . Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res. 2004; 103(1-2):91-5. DOI: 10.1016/j.virusres.2004.02.019. View

19.

Sambhara S, Poland G . Avian influenza vaccines: what's all the flap?. Lancet. 2006; 367(9523):1636-8. DOI: 10.1016/S0140-6736(06)68657-1. View

20.

Treanor J, Campbell J, Zangwill K, Rowe T, Wolff M . Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med. 2006; 354(13):1343-51. DOI: 10.1056/NEJMoa055778. View